Continuous positive airway pressure

ProSomnus® Sleep Technologies to Present Data Showcasing Efficacy of Novel Oral Appliance Therapy Devices for Treatment of Obstructive Sleep Apnea at World Sleep Congress 2022

Retrieved on: 
Friday, March 11, 2022
Hypertension, Snoring, Patient, Compliance, Congress, Research, AHI, MIP, Sleep, Choking, Continuous positive airway pressure, Obstructive sleep apnea, MOG, Entrepreneurship, MD, Heart failure, Observation, Jaw, GLOBE, CPAP, Stroke, REI, Digital Archives, Somnolence, OAT, SAN, Pharmaceutical industry

ProSomnus will share the data in four poster presentations at the World Sleep Congress 2022, being held from March 11-16, 2022, in Rome, Italy.

Key Points: 
  • ProSomnus will share the data in four poster presentations at the World Sleep Congress 2022, being held from March 11-16, 2022, in Rome, Italy.
  • After being treated with the ProSomnus EVO, the patients demonstrated an average AHI reduction of 75 percent, from 26.4 to 6.6.
  • These studies further validate ProSomnuss OATs and the World Sleep Congress is a great stage on which to demonstrate the efficacy of our innovative devices.
  • With more than 135,000 patients treated, ProSomnuss devices are the most prescribed OATs in the U.S. To learn more, visit www.ProSomnus.com .

FDA Orders Philips Respironics to Notify Patients Regarding the Recall of Certain Breathing Assistance Machines

Retrieved on: 
Friday, March 11, 2022
Device, Federal Food, Drug, and Cosmetic Act, Risk, Public health, Ozone, FDA Center for Devices and Radiological Health, FDA, Communication, Regulation of tobacco by the U.S. Food and Drug Administration, Continuous positive airway pressure, Non-invasive ventilation, Philips, Language, Patient, CPAP, Center, Respironics, Frustration, Food, DME, Medical device

Along with these actions, the FDA recommends additional measures Philips can take to better communicate with the public regarding the recall.

Key Points: 
  • Along with these actions, the FDA recommends additional measures Philips can take to better communicate with the public regarding the recall.
  • The FDA also recommends that Philips provide detailed information to device users, DME suppliers, distributors, retailers, and healthcare providers on the replacement process.
  • In June 2021, Philips Respironics initiated a recall of certain ventilators, CPAP and BiPAP machines due to potential health risks related to PE-PURsound abatement foam used in those devices.
  • The order directs Philips to provide the notification described in the order within 45 days of its issuance.

Smart Sensors Market worth $104.5 billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Wednesday, March 9, 2022
Smart sensor, Safety, USD, Maintenance, Tablet, Temperature, Television, Continuous positive airway pressure, Wireless, Electronics, Adoption, MEMS, Push switch, Image sensor, Motion, Research report, City, CPAP, IOT, Personal computer, COVID-19, Region, Growth, CAGR, Instrumentation, Technology

Key factors fueling this markets growth include surging demand for smart sensors in IoT-based devices and consumer electronics; increasing use of smart sensors in revolutionizing industries; high demand for smart sensors by automobile manufacturers to deliver enhanced safety and comfort; and accelerating use of wireless technology to monitor and control security devices equipped with smart sensors.

Key Points: 
  • Key factors fueling this markets growth include surging demand for smart sensors in IoT-based devices and consumer electronics; increasing use of smart sensors in revolutionizing industries; high demand for smart sensors by automobile manufacturers to deliver enhanced safety and comfort; and accelerating use of wireless technology to monitor and control security devices equipped with smart sensors.
  • MEMS technology to dominate Smart Sensors market, in 2021
    The market for MEMS technology-based sensors is estimated to account for the largest share of the overall smart Sensors market, in 2021.
  • The growth of the smart sensors market is driven by the increasing adoption of smart devices such as smart appliances and wearables.
  • Technological developments in smart sensors are leading to advancements in consumer electronics such as smart home appliances and smart TV.

Smart Sensors Market worth $104.5 billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Wednesday, March 9, 2022
Smart sensor, Safety, USD, Maintenance, Tablet, Temperature, Television, Continuous positive airway pressure, Wireless, Electronics, Adoption, MEMS, Push switch, Image sensor, Motion, Research report, City, CPAP, IOT, Personal computer, COVID-19, Region, Growth, CAGR, Instrumentation, Technology

Key factors fueling this markets growth include surging demand for smart sensors in IoT-based devices and consumer electronics; increasing use of smart sensors in revolutionizing industries; high demand for smart sensors by automobile manufacturers to deliver enhanced safety and comfort; and accelerating use of wireless technology to monitor and control security devices equipped with smart sensors.

Key Points: 
  • Key factors fueling this markets growth include surging demand for smart sensors in IoT-based devices and consumer electronics; increasing use of smart sensors in revolutionizing industries; high demand for smart sensors by automobile manufacturers to deliver enhanced safety and comfort; and accelerating use of wireless technology to monitor and control security devices equipped with smart sensors.
  • MEMS technology to dominate Smart Sensors market, in 2021
    The market for MEMS technology-based sensors is estimated to account for the largest share of the overall smart Sensors market, in 2021.
  • The growth of the smart sensors market is driven by the increasing adoption of smart devices such as smart appliances and wearables.
  • Technological developments in smart sensors are leading to advancements in consumer electronics such as smart home appliances and smart TV.

ProSomnus® Sleep Technologies to Present Data on its Oral Appliance Therapy Devices for the Treatment of Obstructive Sleep Apnea at World Sleep Congress 2022

Retrieved on: 
Monday, February 28, 2022
GLOBE, Compliance, Central European, OATS, Stroke, Continuous positive airway pressure, Obstructive sleep apnea, Heart failure, Central European Time, Precision medicine, SAN, Hypertension, Emerging technologies, Patient, MAD, CPAP, OAT, Congress, Research, Pharmaceutical industry

SAN FRANCISCO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- ProSomnus Sleep Technologies, the leader in patient-preferred medical devices for the treatment of Obstructive Sleep Apnea (OSA), will showcase its oral appliance therapy (OAT) devices in four poster abstracts at the World Sleep Congress 2022 , being held from March 11-16, 2022, in Rome, Italy.

Key Points: 
  • SAN FRANCISCO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- ProSomnus Sleep Technologies, the leader in patient-preferred medical devices for the treatment of Obstructive Sleep Apnea (OSA), will showcase its oral appliance therapy (OAT) devices in four poster abstracts at the World Sleep Congress 2022 , being held from March 11-16, 2022, in Rome, Italy.
  • Now in its 16th iteration, the World Sleep Congress is a global scientific meeting that consistently gathers leaders in sleep medicine and research for scientific sessions and networking.
  • The posters showcase:
    The results of a systematic study of the efficacy of ProSomnuss precision oral appliances in treating moderate and severe OSA.
  • ProSomnus medical devices are rapidly emerging as the leading, patient-preferred alternative to CPAP for the treatment of OSA.

LivaNova Announces First Patient Implanted in OSPREY Clinical Study for Patients Coping with Obstructive Sleep Apnea

Retrieved on: 
Thursday, February 24, 2022
Biotechnology, FDA, Health, Other Health, Surgery, Other Science, Mental Health, Research, Medical Devices, General Health, Hospitals, Science, Clinical Trials, Cardiology, Depression, Health, Airway obstruction, Traffic, LivaNova, Critical care, Mask, PLC, Head, Death, Risk, Diabetes, University, Annual report, Sleep apnea, Stroke, Safety, Tongue, Randomized controlled trial, Tampa Bay, Heart failure, Trial of the century, IPG, Hope, RCT, Adult, Continuous positive airway pressure, Morton Plant Hospital, OSA, Principal, News, IDE, Sleep, Hypertension, Hypoglossal nerve, Patient, LIVN, CPAP, University of California, Obstructive sleep apnea, Hospital, Medical device, Pharmaceutical industry, Medicine, LivaNova, BayCare Health System, LIVANOVA, BAYCARE HEALTH SYSTEM

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the first patient implanted in the investigational device exemption (IDE) clinical study, Treating Obstructive Sleep Apnea using Targeted Hypoglossal Neurostimulation ( OSPREY ).

Key Points: 
  • LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the first patient implanted in the investigational device exemption (IDE) clinical study, Treating Obstructive Sleep Apnea using Targeted Hypoglossal Neurostimulation ( OSPREY ).
  • The first OSPREY patient was implanted by Dr. Mitchell Miller at BayCares Morton Plant Hospital in Clearwater, Florida.
  • Throughout the study, independent statisticians will conduct interim data analyses to determine predictive probability of success for OSPREY.
  • Clinical consequences and economic costs of untreated obstructive sleep apnea syndrome World Journal of Otorhinolaryngology-Head and Neck Surgery 2015; 1: 17-27.

Signifier Medical Technologies is Granted HCPCS Codes for eXciteOSA to Help Patients Access Innovative Technology

Retrieved on: 
Tuesday, February 22, 2022
Biotechnology, Mental Health, Medical Devices, Health, Pharmaceutical, Diabetes, Center, Stroke, Obstructive sleep apnea, McNicholas, OSA, Hypertension, Literature review, Solution, Incidence, Snoring, Depression, The New England Journal of Medicine, Centers for Medicare & Medicaid Services, Hypopnea, Veni, vidi, vici, Man, Sleep apnea, LLC, Multimedia, Kotecha, Maintenance, Quality of life, DME, Population health, Medicare, Population, HCPCS, Moyamoya disease, NMES, Heart failure, Continuous positive airway pressure, Observational study, TIA, Sleep, Patient, Signified and signifier, CMS, Health, Physician, Death, Association, Sleep-related breathing disorder, PubMed, Meta-analysis, Electricity, Ageing, JAMA Internal Medicine, News, FDA, Lancet, Health technology, Cardiovascular disease, Medical device, Hospital, Pharmaceutical industry, Wood drying, Silviculture, Dudley Benjafield, Signifier Medical Technologies, eXciteOSA®, Snoring and Obstructive Sleep Apnea, SIGNIFIER MEDICAL TECHNOLOGIES, EXCITEOSA®, SNORING AND OBSTRUCTIVE SLEEP APNEA

We welcome CMS decision to establish two new codes to describe the eXciteOSA device, said Akhil Tripathi, Chief Executive Officer at Signifier.

Key Points: 
  • We welcome CMS decision to establish two new codes to describe the eXciteOSA device, said Akhil Tripathi, Chief Executive Officer at Signifier.
  • HCPCS codes play a critical role in providing patients with access to new medical devices, often improving payment options and healthcare decisions, said Dr. Marc Benton, a New Jersey-based pulmonologist and sleep medicine specialist.
  • The eXciteOSA is a non-invasive, easy to use therapy that does not require patients to wear any sort of device during the night.
  • Unlike other devices which are used while patients sleep, eXciteOSA is the first commercially available device used while awake.

Global Sleep Apnea Diagnostics Market Analysis Report 2021-2028: Telemedicine Gaining Prominence - Market to Reach $685 Million - ResearchAndMarkets.com

Retrieved on: 
Friday, February 4, 2022
Health, General Health, Diagnosis, Growth, Obstructive sleep apnea, Continuous positive airway pressure, COVID-19, CAGR, Sleep, Prevalence, Sleep apnea, Polysomnography, PSG, Industry, Sleep disorder, Hospital, Pharmaceutical industry

The "Sleep Apnea Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Sleep Apnea Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Factors such as increased sleep apnea prevalence, technological developments, and rising geriatric population are boosting the sleep apnea diagnostics market growth.
  • Sleep apnea devices are primarily provided as diagnostic and therapeutic devices in order to treat obstructive sleep apnea syndrome, central sleep apnea syndrome and complex sleep apnea syndrome.
  • The sleep apnea diagnostics market, based on product, is segmented into polysomnography (PSG) device, home sleep testing devices, oximeter, actigraphy monitoring device, sleep apnea screening device.

Vivos Therapeutics’ mmRNA Oral Appliance Now Eligible for Medicare Reimbursement

Retrieved on: 
Tuesday, December 14, 2021
Snoring, Therapy, U.S. Securities and Exchange Commission, Technology, Science and technology in Asia, Heart failure, Sleep apnea, Stroke, Securities Exchange Act of 1934, Drug Quality and Security Act, Adult, Obstructive sleep apnea, Data analysis, Securities Act of 1933, NASDAQ, Dentist, SEC, PDAC, Risk, OSA, Continuous positive airway pressure, Center, Conditional sentence, Patient, Tissue, Security (finance), Prevalence, VIP, Dementia, Program, Apnea–hypopnea index, Birth, GLOBE, CPAP, Diabetes, Pharmaceutical industry, Coding, Medicare, Vivos

HIGHLANDS RANCH, Colo., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (OSA) and snoring, today announced that it has received acceptance from a Centers for Medicare & Medicaid Services Pricing, Data Analysis and Coding (“PDAC”) contractor for its mmRNA (modified mandibular Repositioning Nighttime Appliance) device for treating mild to moderate OSA and snoring in adults. This acceptance places the mmRNA device on the PDAC list of oral appliances covered by and billable to Medicare. 

Key Points: 
  • This acceptance places the mmRNA device on the PDAC list of oral appliances covered by and billable to Medicare.
  • This development immediately makes benefits of the mmRNA device available to millions of Medicare beneficiaries who seek effective treatment for mild to moderate OSA.
  • The mmRNA is the first and only appliance on the PDAC list that offers patients the compelling clinical advantages of Vivos proprietary technology.
  • Vivos believes that its Vivos System oral appliance technology represents the first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-effective solution for adults with mild-to-moderate OSA.

Bleep, LLC Wins $1.7m NIH SBIR Grant Award For Pap Innovation

Retrieved on: 
Thursday, December 2, 2021
Eclipse, Patient, Insurance, Technology, SBIR, NIH, Population, CAGR, AHI, Compliance, Hypertension, Health, CPAP, Obstructive sleep apnea, Sleep, National, OSA, PAP, SKU, Bleep, Continuous positive airway pressure, LLC, Claustrophobia, FDA, Sleep apnea, Immunization, Pharmaceutical industry

has been awarded a $1.7 million SBIR grant from the National Institutes of Health (NIH) to optimize positive airway pressure (PAP) mask design for use in home and acute care/hospital settings.

Key Points: 
  • has been awarded a $1.7 million SBIR grant from the National Institutes of Health (NIH) to optimize positive airway pressure (PAP) mask design for use in home and acute care/hospital settings.
  • Bleep, LLC hopes to add value in patient comfort and compliance with PAP therapy and may help reduce healthcare costs related to lack of PAP compliance.
  • "Bleep has the only clinically proven no leak PAP on the market, and the only fully made in USA PAP mask.
  • With this NIH grant, Bleep, LLC will optimize its Eclipse PAP technology and produce validation data necessary for successful market commercialization.